These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1521 related articles for article (PubMed ID: 35309297)

  • 1. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis.
    Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D
    Front Immunol; 2022; 13():846753. PubMed ID: 35309297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients.
    Picchianti-Diamanti A; Aiello A; Laganà B; Agrati C; Castilletti C; Meschi S; Farroni C; Lapa D; Najafi Fard S; Cuzzi G; Cimini E; Grassi G; Vanini V; Di Rosa R; Salemi S; Nalli G; Salmi A; Repele F; Altera AMG; Maffongelli G; Palazzolo C; Vita S; Leone S; Puro V; Capobianchi MR; Ippolito G; Nicastri E; Goletti D
    Front Immunol; 2021; 12():740249. PubMed ID: 34594343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors influencing the SARS-CoV-2 infection and vaccination induced immune response in rheumatoid arthritis.
    Nemeth D; Vago H; Tothfalusi L; Ulakcsai Z; Becker D; Szabo Z; Rojkovich B; Merkely B; Nagy G
    Front Immunol; 2022; 13():960001. PubMed ID: 36311767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of booster with BNT162b2 mRNA in SARS-CoV-2 vaccination in patients with rheumatoid arthritis.
    Benucci M; Damiani A; Gobbi FL; Lari B; Grossi V; Infantino M; Manfredi M
    Immunol Res; 2022 Aug; 70(4):493-500. PubMed ID: 35543863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal study.
    Farroni C; Aiello A; Picchianti-Diamanti A; Laganà B; Petruccioli E; Agrati C; Garbuglia AR; Meschi S; Lapa D; Cuzzi G; Petrone L; Vanini V; Salmi A; Altera AMG; Repele F; Grassi G; Bettini A; Vita S; Mariano A; Damiani A; Infantino M; Grossi V; Manfredi M; Niccoli L; Puro V; Rosa RD; Salemi S; Sesti G; Scolieri P; Bruzzese V; Benucci M; Cantini F; Nicastri E; Goletti D
    Int J Infect Dis; 2022 Dec; 125():195-208. PubMed ID: 36328289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies.
    Tortorella C; Aiello A; Gasperini C; Agrati C; Castilletti C; Ruggieri S; Meschi S; Matusali G; Colavita F; Farroni C; Cuzzi G; Cimini E; Tartaglia E; Vanini V; Prosperini L; Haggiag S; Galgani S; Quartuccio ME; Salmi A; Repele F; Altera AMG; Cristofanelli F; D'Abramo A; Bevilacqua N; Corpolongo A; Puro V; Vaia F; Capobianchi MR; Ippolito G; Nicastri E; Goletti D;
    Neurology; 2022 Feb; 98(5):e541-e554. PubMed ID: 34810244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced humoral response to a third dose (booster) of SARS-CoV-2 mRNA vaccines by concomitant methotrexate therapy in elderly patients with rheumatoid arthritis.
    Stahl D; Tho Pesch C; Brück C; Esser RL; Thiele J; Di Cristanziano V; Kofler DM
    RMD Open; 2022 Oct; 8(2):. PubMed ID: 36216409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of specific RBD
    Del Pino Molina L; Bravo Gallego LY; Nozal P; Soto-Serrano Y; Martínez-Feito A; Reche-Yebra K; González-Torbay A; Cuesta-Martín de la Cámara R; Gianelli C; Cámara C; González-García J; González-Muñoz M; Rodríguez-Pena R; López Granados E
    Front Immunol; 2023; 14():1136308. PubMed ID: 37215146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines.
    Isnardi CA; Cerda OL; Landi M; Cruces L; Schneeberger EE; Montoro CC; Alfaro MA; Roldán BM; Gómez Vara AB; Giorgis P; Ezquer RA; Crespo Rocha MG; Reyes Gómez CR; de Los Ángeles Correa M; Rosemffet MG; Abarza VC; Pellet SC; Perandones M; Reimundes C; Longueira Y; Turk G; Quiroga MF; Laufer N; Quintana R; de la Vega MC; Kreplak N; Pifano M; Maid P; Pons-Estel GJ; Citera G
    J Rheumatol; 2022 Dec; 49(12):1385-1389. PubMed ID: 36182107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab.
    Achiron A; Mandel M; Dreyer-Alster S; Magalashvili D; Menascu S; Warszawer Y; Dolev M; Didikin M; Harari G; Sonis P; Falb R; Gurevich M
    Mult Scler Relat Disord; 2023 Apr; 72():104616. PubMed ID: 36933299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responses.
    Saleem B; Ross RL; Bissell LA; Aslam A; Mankia K; Duquenne L; Corsadden D; Carter C; Hughes P; Nadat FA; Mulipa P; Lobb M; Clarke B; Mbara K; Morton R; Dibb S; Chowdhury R; Newton D; Pike A; Kakkar V; Savic S; DelGaldo F; Emery P
    RMD Open; 2022 Mar; 8(1):. PubMed ID: 35365569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limited Humoral and Specific T-Cell Responses After SARS-CoV-2 Vaccination in PWH With Poor Immune Reconstitution.
    Benet S; Blanch-Lombarte O; Ainsua-Enrich E; Pedreño-Lopez N; Muñoz-Basagoiti J; Raïch-Regué D; Perez-Zsolt D; Peña R; Jiménez E; Rodríguez de la Concepción ML; Ávila C; Cedeño S; Escribà T; Romero-Martín L; Alarcón-Soto Y; Rodriguez-Lozano GF; Miranda C; González S; Bailón L; Blanco J; Massanella M; Brander C; Clotet B; Paredes R; Esteve M; Izquierdo-Useros N; Carrillo J; Prado JG; Moltó J; Mothe B
    J Infect Dis; 2022 Nov; 226(11):1913-1923. PubMed ID: 36200261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Waning humoral immunity of SARS-CoV-2 vaccination in a rheumatoid arthritis cohort and the benefits of a vaccine booster dose.
    Le Moine C; Soyfoo MS; Mekkaoui L; Dahma H; Tant L
    Clin Exp Rheumatol; 2023 Jan; 41(1):82-87. PubMed ID: 35699073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humoral and cellular immune responses in persons with rheumatoid arthritis after a third dose of mRNA COVID-19 vaccine.
    Tedeschi SK; Solomon DH; Chen Y; Ellrodt J; Whelan MG; Stratton J; Hayashi K; Whiteman NB; Chen L; Adejoorin I; Marks KE; Gomez-Rivas E; Rao DA; Jonsson AH; Wesemann DR
    Semin Arthritis Rheum; 2023 Apr; 59():152177. PubMed ID: 36796211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
    Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
    Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence of immune response to BNT162b2 COVID-19 vaccine in systemic lupus erythematosus patients treated with Belimumab.
    Schiavoni I; Olivetta E; Natalucci F; Olivieri G; Lo Presti A; Fedele G; Stefanelli P; Ceccarelli F; Conti F
    Lupus; 2023 Mar; 32(3):394-400. PubMed ID: 36607313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response.
    Filippini F; Giacomelli M; Bazzani C; Fredi M; Semeraro P; Tomasi C; Franceschini F; Caruso A; Cavazzana I; Giagulli C
    BMC Med; 2023 Jun; 21(1):210. PubMed ID: 37316832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count.
    Antinori A; Cicalini S; Meschi S; Bordoni V; Lorenzini P; Vergori A; Lanini S; De Pascale L; Matusali G; Mariotti D; Cozzi Lepri A; Gallì P; Pinnetti C; Gagliardini R; Mazzotta V; Mastrorosa I; Grisetti S; Colavita F; Cimini E; Grilli E; Bellagamba R; Lapa D; Sacchi A; Marani A; Cerini C; Candela C; Fusto M; Puro V; Castilletti C; Agrati C; Girardi E; Vaia F;
    Clin Infect Dis; 2022 Aug; 75(1):e552-e563. PubMed ID: 35366316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study.
    Lasagna A; Bergami F; Lilleri D; Percivalle E; Quaccini M; Alessio N; Comolli G; Sarasini A; Sammartino JC; Ferrari A; Arena F; Secondino S; Cicognini D; Schiavo R; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
    ESMO Open; 2022 Apr; 7(2):100458. PubMed ID: 35427842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 77.